Issue Archive

In this commissioned series of reviews introduced by Associate Editor Jean Soulier, experts provide new insights into the pathobiology of secondary acute myeloid leukemias arising in diverse genetic or acquired, benign or malignant hematologic disorders.

In a study reported in this Plenary Paper, Pi and colleagues used unbiased genomic profiling approaches and mechanistic studies to identify the direct and indirect target sites of the oncogenic fusion protein E2A-PBX1 in t(1,19)-positive pre-B acute lymphoblastic leukemia cells. They revealed how E2A-PBX1 acts in concert with RUNX1 to enforce transcriptome alterations underpinning the development of leukemia.

In this commissioned series of reviews introduced by Associate Editor Jean Soulier, experts provide new insights into the pathobiology of secondary acute myeloid leukemias arising in diverse genetic or acquired, benign or malignant hematologic disorders.

In this commissioned series of reviews introduced by Associate Editor Jean Soulier, experts provide new insights into the pathobiology of secondary acute myeloid leukemias arising in diverse genetic or acquired, benign or malignant hematologic disorders.

In this commissioned series of reviews introduced by Associate Editor Jean Soulier, experts provide new insights into the pathobiology of secondary acute myeloid leukemias arising in diverse genetic or acquired, benign or malignant hematologic disorders.

In this commissioned series of reviews introduced by Associate Editor Jean Soulier, experts provide new insights into the pathobiology of secondary acute myeloid leukemias arising in diverse genetic or acquired, benign or malignant hematologic disorders.

Palladini et al provide early results of a prospective trial of subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone as first-line therapy for AL amyloidosis. They report that the regimen has high complete hematological and organ response rates and that toxicity is as expected with these classes of drugs.

Arising in a screen to identify mitochondrial gene products necessary for the growth of acute myeloid leukemia (AML) cells, mitochondrial carrier homolog 2 (MTCH2) is shown to influence the differentiation of AML cells by toggling histone acetylation downstream of regulation of pyruvate metabolism.

In a randomized phase 2 trial of acalabrutinib in patients with chronic lymphocytic leukemia (CLL), Sun et al documented that twice-daily dosing achieves higher Bruton tyrosine kinase (BTK) occupancy and pathway inhibition in lymph nodes than once-daily dosing and established the rate of BTK resynthesis in CLL cells. Both findings support the rationale for twice-daily dosing with this drug.

Shide and colleagues separated the functional roles of loss of a normal CALR allele and gain of a mutant CALR allele in murine models of CALR-driven essential thrombocythemia, providing insights into the development of some myeloproliferative neoplasms and stem cell biology.

Jiang et al used murine models to reveal critical nonenzymatic roles for acylglycerol kinase (AGK) in megakaryocyte differentiation and platelet biogenesis by enhancing JAK2/STAT3 signaling triggered by thrombopoietin.

Markey and colleagues investigated the relationship between the gastrointestinal microbiome and chronic graft-versus-host disease (cGVHD), revealing that lower systemic concentrations of microbe-derived butyrate and propionate are associated with a higher chance of developing cGVHD in allogeneic hematopoietic stem cell transplant patients.

Tremblay and colleagues asked whether patients receiving either routine anticoagulation or antiplatelet therapy for existing conditions prior to becoming ill with COVID-19 have different outcomes from patients receiving neither therapy. After matching for existing comorbidities, this retrospective observational study finds no evidence for an effect of prediagnosis anticoagulation on mortality.